No Data
I-Mab BioPharma-B (01541): IMM0306 has been approved by the National Medical Products Administration for phase II clinical trials for the treatment of lupus nephritis.
Yiming Anco-B (01541) announced that the group has been approved by the National Medical Products Administration of the People's Republic of China to proceed...
Express News | ImmuneOnco Biopharmaceuticals Shanghai - Approval by Nmpa for Phase II Clinical Trial of Imm0306 for Treatment of Lupus Nephritis
E-miniangu-B (01541.HK) plans to allocate a total of 33.15 million new H-shares, with a total fundraising of 0.234 billion Hong Kong dollars.
KeLongHui November 21st | Yiming Ounc-B (01541.HK) issued an announcement. On November 21, 2024, the company entered into a placing agreement with China International Capital Corporation (as the placing agent). According to this, the placing agent has agreed to act as the company's exclusive placing agent and will endeavor to persuade subscribers to subscribe for a total of 33.15 million new H shares at a placing price of HK$7.05 per share in accordance with the terms set out in the placing agreement and subject to the conditions set out in such agreement. The placing shares represent approximately 8.86% and 9.50% of the company's issued share capital and total issued H shares as of the date of this announcement, and of the shares issued
Express News | ImmuneOnco Biopharmaceuticals Shanghai Inc - Placing of New H Shares
Yiming Enke-B (01541.HK) announced positive clinical trial results for IMM0306 combined with lenalidomide treatment for chronic lymphoma.
Gelonghui, November 18 - Yiming Anke-B (01541.HK) announced that the Phase Ib/IIa clinical trial of IMM0306 in combination with lenalidomide for the treatment of chronic lymphocytic leukemia has recruited a total of 27 evaluable patients (25 patients with follicular lymphoma (FL) and two patients with marginal zone lymphoma (MZL)) as of October 26, 2024. The following figure illustrates the efficacy data for patients with relapsed or refractory (R/R) FL as of October 26, 2024: as of October 26, 2024, the overall response rate in 25 evaluable R/R FL patients is...
Express News | Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
No Data
No Data